SCHEMBL4922756

SCHEMBL4922756

CCc1ccc(NC(=O)Nc2ccc(N3CCCCC3)c(F)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.53
NPC1 O15118 8/20 0.53
KMT2A Q03164 3/20 0.53
MAPT P10636 8/20 0.53
ALDH1A1 P00352 3/20 0.53
HPGD P15428 3/20 0.53
TSHR P16473 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
MEN1 O00255 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
TP53 P04637 2/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 1/20 0.48
OPRM1 P35372 1/20 0.47
OPRD1 P41143 1/20 0.47
HTT P42858 1/20 0.47
GAA P10253 1/20 0.47
PKM P14618 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923650 0.86 NPC1 (0.55) RAB9ANPC1KMT2AMAPTALDH1A1
SCHEMBL4920398 0.85 MAPT (0.63) RAB9ANPC1KMT2AMAPTALDH1A1
SCHEMBL5176497 0.84 CNR1 (0.57) RAB9ANPC1KMT2AMAPTALDH1A1
SCHEMBL4920276 0.84 CNR1 (0.57) RAB9ANPC1KMT2AMAPTALDH1A1
SCHEMBL4922838 0.84 CNR1 (0.57) RAB9ANPC1KMT2AMAPTALDH1A1
SCHEMBL4920895 0.83 MEN1 (0.58) RAB9ANPC1KMT2AMAPTALDH1A1
SCHEMBL4919660 0.82 CNR1 (0.59) RAB9ANPC1KMT2AMAPTALDH1A1
SCHEMBL4923530 0.82 MAPT (0.57) RAB9ANPC1KMT2AMAPTALDH1A1
SCHEMBL4917218 0.81 EPHX2 (0.57) RAB9ANPC1KMT2AMAPTSMN1; SMN2
SCHEMBL4924588 0.81 CNR1 (0.53) RAB9AKMT2AMAPTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R RAB9A 3359/4885NPC1 148/4885KMT2A 1905/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R RAB9A 3359/4885NPC1 148/4885KMT2A 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.